BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 16392308)

  • 1. [Acute renal failure and hypertension].
    Bellido D; Sánchez de la Nieta MD; Vozmediano C; Oteros R; Zarca MA; Nieto J; Rivera F
    Nefrologia; 2005; 25(5):563-7. PubMed ID: 16392308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth.
    Bos-Thompson MA; Hillaire-Buys D; Muller F; Dechaud H; Mazurier E; Boulot P; Morin D
    Ann Pharmacother; 2005 Jan; 39(1):157-61. PubMed ID: 15590878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fetal toxicity of angiotensin-II-receptor inhibitors. Case report].
    Roger N; Popovic I; Madelenat P; Mahieu-Caputo D
    Gynecol Obstet Fertil; 2007 Jun; 35(6):556-60. PubMed ID: 17544313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valsartan. Just a second-line antihypertensive drug.
    Can Fam Physician; 1999 Nov; 45():2626-8, 2630-3. PubMed ID: 10587770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lithium intoxication after valsartan treatment.
    Su YP; Chang CJ; Hwang TJ
    Psychiatry Clin Neurosci; 2007 Apr; 61(2):204. PubMed ID: 17362443
    [No Abstract]   [Full Text] [Related]  

  • 6. [New effective dosage of valsartan. High dosage--effective against high blood pressure].
    MMW Fortschr Med; 2007 Nov; 149(46):52-3. PubMed ID: 18069195
    [No Abstract]   [Full Text] [Related]  

  • 7. Angiotensin receptor blockers and myocardial infarction: the importance of dosage.
    Sarzani R; Dessì-Fulgheri P
    J Hypertens; 2006 Aug; 24(8):1679-81; author reply 1681-2. PubMed ID: 16877973
    [No Abstract]   [Full Text] [Related]  

  • 8. Angiotensin receptor blockers and myocardial infarction.
    Verma S; Strauss M
    BMJ; 2004 Nov; 329(7477):1248-9. PubMed ID: 15564232
    [No Abstract]   [Full Text] [Related]  

  • 9. Two amlodipine/ARB combinations for hypertension.
    Med Lett Drugs Ther; 2007 Dec; 49(1276):101-2. PubMed ID: 18084152
    [No Abstract]   [Full Text] [Related]  

  • 10. [Scientific evidence--applied in routine general practice. Successful decrease in pressure and risk].
    MMW Fortschr Med; 2006 May; 148(18):42-3. PubMed ID: 16736689
    [No Abstract]   [Full Text] [Related]  

  • 11. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olmesartan associated with acute renal failure in a patient with bilateral renal artery stenosis.
    Bavbek N; Kasapoglu B; Isik A; Kargili A; Kirbas I; Akcay A
    Ren Fail; 2010; 32(9):1115-7. PubMed ID: 20863218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
    He YL; Ligueros-Saylan M; Sunkara G; Sabo R; Zhao C; Wang Y; Campestrini J; Pommier F; Dole K; Marion A; Dole WP; Howard D
    J Clin Pharmacol; 2008 Jan; 48(1):85-95. PubMed ID: 17986525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New clinical investigations with selective angiotensin II receptor blocker therapy in diabetes and renal disease.
    Ruilope LM
    J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2 Suppl):S29-31. PubMed ID: 17199217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the angiotensin II type 1 receptor antagonist valsartan on the expression of superoxide dismutase in hypertensive patients.
    Yang HY; Kao PF; Chen TH; Tomlinson B; Ko WC; Chan P
    J Clin Pharmacol; 2007 Mar; 47(3):397-403. PubMed ID: 17322151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Valsartan improves symptoms and quality of life in patients with chronic heart failure].
    Baumhäkel M; Müller U; Böhm M
    MMW Fortschr Med; 2008 Apr; 150 Suppl 1():48-53. PubMed ID: 18540333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valsartan-induced drug eruption followed by CD30+ pseudolymphomatous eruption.
    Sawada Y; Yoshiki R; Kawakami C; Fukamachi S; Sugita K; Nakamura M; Tokura Y
    Acta Derm Venereol; 2010 Sep; 90(5):521-2. PubMed ID: 20814632
    [No Abstract]   [Full Text] [Related]  

  • 18. Exanthematous drug eruption due to valsartan.
    Ozturk G; Turk BG; Senturk B; Turkmen M; Kandiloglu G
    Cutan Ocul Toxicol; 2012 Dec; 31(4):335-7. PubMed ID: 22257082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dilemma of antihypertensive therapy: high blood pressure diminishes, potency sometimes, too].
    MMW Fortschr Med; 2006 Sep; 148(38):17. PubMed ID: 17036956
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.
    Andrés A; Morales E; Morales JM; Bosch I; Campo C; Ruilope LM;
    Transplant Proc; 2006 Oct; 38(8):2419-23. PubMed ID: 17097955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.